CWAN

Clearwater Analytics - Enfusion Deal Receives U.S. Antitrust Approval

(RTTNews) - Clearwater Analytics Holdings Inc. (CWAN) and Enfusion Inc. (ENFN) announced the expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, in connection with Clearwater's proposed acquisition of Enfusion. The expiration of the waiting period occurred at 11:59 p.m. on February 24, 2025.

The expiration of the waiting period under the HSR Act satisfies one of the closing conditions for the completion of the transaction.

The transaction is expected to close in the second quarter of 2025, subject to the satisfaction or waiver of customary closing conditions including the receipt of Enfusion shareholder approval.

Last month, Clearwater Analytics agreed to acquire Enfusion for $11.25 per share, which consists of $5.85 per share in cash and $5.40 per share in Clearwater Class A stock.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

Tags

More Related Articles

Info icon

This data feed is not available at this time.

Data is currently not available

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.